Changes in antihypertensive drug treatment in the general population: the Colaus Study

Details

Serval ID
serval:BIB_3383BC92F151
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Poster: Summary – with images – on one page of the results of a researche project. The summaries of the poster must be entered in "Abstract" and not "Poster".
Collection
Publications
Institution
Title
Changes in antihypertensive drug treatment in the general population: the Colaus Study
Title of the conference
Swiss Public Health Conference 2012
Author(s)
Christe V., Waeber G., Vollenweider P., Marques-Vidal P.M.
Address
Lausanne, Switzerland, August 30-31, 2012
Publication state
Published
Issued date
2012
Language
english
Abstract
Background and aims: there is little information regar ding changes in antihypertensive drug treatment in Switzerland. We aimed at assessing those changes in a population-based, prospective study.
Methods: 768 hypertensive subjects (372 women, 397 men) followed for 5 years. Subjects
were defined as continuers (no change), switchers (one antihypertensive class replace by another), combiners (one antihypertensive class added) and discontinuers (stopped treatment).
Results: Analysis of all patients (mono or combination therapy) showed that 54.6% were continuers, 27.2% combiners, 12.9% switchers and 5.3 % discontinuers. Similar findings were obtained for participants on monotherapy only: 42.2% continuers, 36.7% combiners, 13.4% switchers and 7.7% discontinuers. Combiners had higher systolic and diastolic blood pressure values at baseline than the other groups (p<0.001), while no difference were found for personal and family history and other clinical and biological variables. Compared to continuers, combiners and switchers improved their blood pressure status at follow-up: 26.7% of combiners and 26.3% of switchers improved, versus 17.7% of continuers and 7.3% of
discontinuers (p<0.001). Among participants on monotherapy at baseline, continuation was greatest for angiotensin II type 1 receptor blocking agents (ARBs, 53.1%), angiotensin-converting enzyme inhibitors (44.4%) and β-blockers (41.8%). Only one quarter of participants
treated with diuretic or calcium channel blockers at baseline remained so at follow-up.
Conclusion: Antihypertensivedrug treatment is very stable in Switzerland. There are no big differences in persistence between antihypertensive classes, even if ARBs had the most favorable utilization pattern. Changes are only due to blood pressure level and improve blood pressure status.
Create date
16/03/2013 11:30
Last modification date
20/08/2019 13:19
Usage data